Investigational drug · Phase 3
NTLA-2002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hereditary Angioedema.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "NTLA-2002"
First trial start
2025
Jan 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NTLA-2002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hereditary Angioedema
Approved drugs for the same conditions: Hereditary angioedema · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "NTLA-2002" as an intervention, largest first.
- HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)Pivotal-lookingActive, not recruiting
Intellia TherapeuticsIndustry
NCT06634420 · 80 participants · Start Jan 15, 2025 · Primary completion Feb 10, 2026
Drug: NTLA-2002; Normal Saline IV Administration · For: Hereditary Angioedema
Sites: Scottsdale, Arizona; San Diego, California; Santa Monica, California · 29 sites in all
- NTLA-2002 in Adults With Hereditary Angioedema (HAE)Active, not recruiting
Intellia TherapeuticsIndustry
NCT05120830 · 37 participants · Start Dec 10, 2021 · Primary completion Apr 4, 2024
Drug: Biological NTLA-2002 · For: Hereditary Angioedema
Sites: Campbelltown, Australia; Grenoble, France; Lille, France · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- [Current and future therapies for bradykinin-mediated angioedema].
Fasshauer M, Dominas N · Dermatologie (Heidelb) 2026
- Lonvoguran ziclumeran: a CRISPR-CAS9-based gene therapy for the treatment of hereditary angioedema.
Luong LH, Stone S, Bui V, et al. · Expert Opin Investig Drugs 2026
- CRISPR-Cas9 gene editing for hereditary angioedema: current treatments and emerging therapies.
Jalal L, Taimuri MA, Sumbal A, et al. · Ann Med Surg (Lond) 2025
- CRISPR-Based Therapy for Hereditary Angioedema.
Cohn DM, Gurugama P, Magerl M, et al. · N Engl J Med 2025
- Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema.
Riedl MA, Bordone L, Revenko A, et al. · J Allergy Clin Immunol Pract 2024
- Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies.
Farkas H, Balla Z · Expert Opin Investig Drugs 2024
Also in development for Hereditary Angioedema
- siRNAADX-038, ADX-324Phase 37 trials
ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1
- DeucrictibantPHVS416, PHA121Phase 35 trials
Pharvaris Netherlands B.V. · Hereditary Angioedema (HAE), Hereditary Angioedema, Hereditary Angioedema Type I
- KVD900Phase 33 trials
KalVista Pharmaceuticals, Ltd. · Hereditary Angioedema
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.